APA: Geodon Found More Effective Than Haldol in Emergency Control of Psychotic Symptoms In Schizophrenia
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




APA: Geodon Found More Effective Than Haldol in Emergency Control of Psychotic Symptoms In Schizophrenia

By Mark Moran

Philadelphia, PA -- May 22, 2002 -- Intramuscular ziprasidone (Geodon) appears to be more effective than intramuscular haloperidol (Haldol) in relieving acute psychotic symptoms among schizophrenics in emergency settings.

David G. Daniel, MD, of George Washington University, Washington, DC, presented the findings at the 155th annual meeting of the American Psychiatric Association (APA). The research was supported by Pfizer, Inc., which manufactures Geodon.

An open-label study involving more than 500 patients showed that those who were treated with intramuscular ziprasidone experienced comparable improvement in agitation and greater improvement in psychotic symptoms compared to patients who received intramuscular haloperidol.

Patients received medication by intramuscular injection during the first one-to-three days of treatment. After up to three days of intramuscular dosing, all patients were transitioned to oral therapy for continued management of their schizophrenia symptoms for six weeks.

Psychotic symptoms such as hallucinations and agitation were measured by standard assessment scales.

The improvement seen in the ziprasidone patients was either sustained or increased when they transitioned to oral therapy. In addition, patients treated with ziprasidone during intramuscular administration and oral phases of the study showed a significantly lower incidence of movement disorders than those who received Haldol.

Dr. Daniel pointed out that rapid control of psychotic agitation, particularly in the emergency setting, was imperative. Intramuscular ziprasidone was hence an important option for physicians as it can rapidly bring agitated patients under control with a low liability for the movement side effects that can be so frightening and debilitating to the patient.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities